Active surveillance for prostate cancer: A review

Archivos Espanoles de Urologia

Volumn 64, Issue 8, 2011, Pages 806-813

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Low risk; Prostate cancer; Review

Indexed keywords

EID: 80055004698     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8.
3. Roobol M, Kerkhof M, Schroder F et al. Prostate cancer mortality reduction by PSA based screening adjusted for non-attendance and contamination in the ERSPC. European Urology 56 (2009): 584-91
4. Sakr, W. A., Haas, G. P., Cassin, B. F. et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol, 150: 379, 1993
5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9.
6. Presti, J. C., Jr.: Prostate biopsy: how many cores are enough? Urol Oncol, 21: 135, 2003
7. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002 Jul 15;95(2):281-6 (Pubitemid 34787593)
8. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep;178(3 Pt 2):S14-9. (Pubitemid 47224952)
9. Albertsen P, Hanley JA, Fine J. 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer JAMA. 2005;293:2095-2101 (Pubitemid 40617061)
10. Albertsen PC, Hanley JA, Barrows GH, Penswon DF, Kowalczyk PD, Sanders MM, Fine J. Prostate Cancer and the Will Rogers Phenomenon Natl Cancer Inst 2005; 97: 1248-1253
11. Draisma G, Schroeder FH et al Lead times and overdetection due to PSA screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003 Jun 18;95(12):868-78 (Pubitemid 36833878)
12. Tornblom M et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004 Jan 1;108(1):122-9. (Pubitemid 37444454)
13. Bill-Axelson A, Holmberg L. Radical prostatectomy versus watchful waiting (update). N Engl J Med. 2005 May 12;352(19):1977-84 (Pubitemid 40638368)
14. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol, 167: 1664, 2002
15. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer. J Clin Oncol. 2010, 1:126-131.
16. Khatami A, Hugusson PSA DT and surveillance: Int J Cancer 120, 170-174 2006
17. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. BJU Int. 2008 Jan;101(2):165-9. (Pubitemid 350294039)
18. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience J Urol 2007 178;6: 2359-2365 (Pubitemid 350052183)
19. Parker, C.: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 5: 101, 2004
20. van As NJ, Parker CC.Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007 Sep-Oct;13(5):289-94
21. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schröder FH.Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.Eur Urol. 2007 May;51(5):1244-50
22. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly. Eur Urol. 2008 Sep 17
23. van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roeme ling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH.Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int. 2009 Oct 8.
24. Shappley W, Chan J Prospective Study of Determinants and Outcomes of Deferred Treatment or Watchful Waiting Among Men With Prostate Cancer in a Nationwide Cohort. Journal of Clinical Oncology, 27 (30) Oct 2009: 4980-4985
25. Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in patients on active surveillance. Journal of Urology 2006: 176(4): pp 1392-7.
26. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004 Jul 8;351(2):125-35
27. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007 Nov;52(5):1309-22 (Pubitemid 47446019)
28. Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, Finelli A, Trachtenberg J, Zlotta A, Fleshner N. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int. 2009 Oct 8
29. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002 Sep 12;347(11):790-6 (Pubitemid 34988337)
30. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M.Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007 Sep;100(3):540-3 (Pubitemid 47205468)
31. Graif T, Loeb S, Roehl KA, Gashti SN, Griffin C, Yu X, Catalona WJ. Under diagnosis and over diagnosis of prostate cancer. J Urol. 2007 Jul;178(1):88-92. (Pubitemid 46908727)
32. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review.Curr Opin Urol. 2009 May;19(3):283-9.
33. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008 Feb 28;358(9):910-9. (Pubitemid 351397090)
34. Thompson, I. M., Goodman, P. J., Tangen, C. M. et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med, 349: 215, 2003
35. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, Pettaway C, et al. Further analyses from the REDUCE prostate cancer risk reduction trial. LBA1, Late Breaking Science Forum, AUA 2009